APM
ACET icon

Avidity Partners Management’s Adicet Bio ACET Stock Holding History

Avidity Partners Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-195,000
Closed -$62.3M – 83
2022
Q1 		$62.3M Buy
195,000
+5,375
+3% +$1.24M 1.3% 26
2021
Q4 		$53.1M Buy
189,625
+38,400
+25% +$6.59M 1.13% 35
2021
Q3 		$19M Buy
151,225
+10,569
+8% +$1.31M 0.42% 55
2021
Q2 		$23.2M Buy
140,656
+1,281
+0.9% +$261K 0.63% 48
2021
Q1 		$29.2M Buy
+139,375
New +$32M 0.81% 46

Other funds holding ACET

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avidity Partners Management's ACET Position: Q2 2022 in Review

Avidity Partners Management sold out of Adicet Bio (ACET) in Q2 2022, closing a stake of 195,000 shares — an estimated $62.3M sold.

Avidity Partners Management first reported a position in ACET in Q1 2021 and held it in 5 quarters. The position peaked at $62.3M in Q1 2022. 101 funds tracked by Wall St. Rank hold ACET as of Q2 2022.

  • Avidity Partners Management reported no remaining Adicet Bio position as of Q2 2022 after selling out during the quarter.
  • Avidity Partners Management sold 195,000 Adicet Bio shares in Q2 2022, an estimated $62.3M.
  • Avidity Partners Management first reported a position in Adicet Bio in Q1 2021 and held it in 5 quarters.
  • Avidity Partners Management's Adicet Bio position peaked at $62.3M in Q1 2022.
  • 101 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2022.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.